• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Nemdatine
    / Abic

    Active Ingredient
    Memantine HCl 10 mg, 20 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    56 X 10 mg

    not in the basket chart 25982

    Related information


    The generally accepted dosage for adults and older people – 20 mg a day. In order to reduce the risk for side effects, take your dosage gradually according to the following schedule: 1st Week: 5 mg a day. 2nd Week: 10 mg a day. 3rd Week: 15 mg a day. 4th Week: and beyond 20 mg a day. The initial dose is half a tablet (5mg) a day during the first week. On the second week, one tablet (10mg) a day. On the third week, 1/2 tablet (5mg) a day. From the 4th week and beyond, one 20 mg tablet or two 10 mg tablets a day.
    Dosage for patients with impaired kidney function: In patients with mild renal impairment (creatinine clearance is 50-80 ml/min), dosage adjustment is not required. In patients with moderate renal impairment (creatinine clearance is 30-49 ml/min), the daily dosage is 10 mg a day. If tolerance to the medicine develops after 7 days of treatment, the dosage may be increased to 20 mg a day.
    In patients with severe renal impairment (CrCl: 5-29 ml/min), the daily dosage is 10 mg a day. Do not exceed the recommended dose.
    Method of use: The tablet should be swallowed with some water. The medicine may be taken with or without food.
    The medicine should be taken once a day.
    The medicine should be taken at the same time each day. The 10 mg tablets may be halved (the tablet has a score line). There is no information regarding pulverization or chewing.


    Treatment of patients with moderate to severe Alzheimer’s disease.


    Hypersensitivity to the active substance or to any of its excipients.

    Special Precautions

    Please refer to the license holder for further details.

    Side Effects

    Please refer to the license holder for further details.

    Actavis LTD, Malta